Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 306 results found since Jan 2013.

Mast cells predict hypersensitive reactions in rituximab desensitization
HOUSTON – For rituximab patients undergoing desensitization, mast cell degranulation is a more effective predictor of hypersensitive reactions (HSR) than are the traditionally employed skin tests, according to a study presented at the annual meeting of the American Academy of Allergy, Asthma, and...
Source: Skin and Allergy News - April 12, 2015 Category: Dermatology Tags: FPN News FPN Allergy & Immunology FPN Rheumatology IMN News IMN Allergy IMN Rheumatology RHEUM News Source Type: news

P337 Remission of cow ’s milk allergy during rituximab therapy: a case report
Food allergy has no known treatment. However, novel therapies are being studied in the hope of promoting tolerance. This case report describes the remission of food allergy during rituximab therapy.
Source: Annals of Allergy, Asthma and Immunology - October 27, 2017 Category: Allergy & Immunology Authors: A. Stachowiak, L. Kerns Source Type: research

Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases
AbstractPurpose of ReviewThe use of biologic therapies has risen exponentially over recent years, allowing for unprecedented disease control within numerous areas of Allergy/Immunology. With this expanded use, awareness and understanding of adverse reactions to biologic agents have also increased.Recent FindingsMultiple biologic adverse reaction phenotypes have been described, but significant overlap in clinical features across phenotypes exists. Given considerable phenotypic overlap, a targeted testing approach may not always be clear, and more recent classifications focus on management decision making using tools of diag...
Source: Current Allergy and Asthma Reports - October 28, 2022 Category: Allergy & Immunology Source Type: research

Prolonged hypogammaglobulinemia after adjuvant rituximab for Hodgkin's lymphoma presenting with refractory urticaria.
PMID: 23176893 [PubMed - in process]
Source: Annals of Allergy, Asthma and Immunology - December 1, 2012 Category: Allergy & Immunology Authors: Wolverton W, McClenathan B Tags: Ann Allergy Asthma Immunol Source Type: research

The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases.
Abstract Biological agents such as monoclonal antibodies and soluble cytokine receptors have taken on an expanding role in the treatment of chronic immune mediated diseases. Progressive multifocal leukoencephalopathy (PML) is a rare central neurological disease caused by JC virus infection that has been described in the setting of conditions with severe impairment of immune surveillance, such as haematological malignancies, stem cell or solid organ transplantation and AIDS. This serious demyelinating disease has recently been described in patients receiving monoclonal antibodies for chronic inflammatory diseases s...
Source: Inflammation and Allergy Drug Targets - February 23, 2014 Category: Allergy & Immunology Authors: Toussirot E, Bereau M Tags: Inflamm Allergy Drug Targets Source Type: research

Biologics for ANCA-Associated Vasculitis.
Abstract The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a group of necrotizing vasculitides with a potential fatal outcome. Conventional therapy is based on the use of glucocorticoids (GCs) and cyclophosphamide (CYC), which is associated with severe toxic effects and is unable to control the disease activity in some refractory and relapsing cases. Several authors focused their efforts on the identification of safe and more efficient drugs, primarily investigating biological agents. Rituximab (RTX) demonstrated to be an alternative to CYC as remission-induction therapy for microsco...
Source: Inflammation and Allergy Drug Targets - July 1, 2014 Category: Allergy & Immunology Authors: Murgia G, Firinu D, Manconi PE, Del Giacco SR Tags: Inflamm Allergy Drug Targets Source Type: research

The use of biologicals in cutaneous allergies – present and future
In conclusion, although currently only one biological is approved in chronic urticaria, there is hope that a rapid better understanding of individual disease factors will support the development of other novel drugs in this field.
Source: Current Opinion in Allergy and Clinical Immunology - October 1, 2014 Category: Allergy & Immunology Tags: SKIN ALLERGY: Edited by Torsten Zuberbier and Thomas Werfel Source Type: research

New drug targets in atopic dermatitis.
Authors: Simon D, Simon HU Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by eczematous skin lesions, pruritus and typical histopathological features. T cells are thought to play a key role, but B cells might also participate in the pathogenesis of AD. In two investigator-initiated pilot studies, we studied the effects of B cell depletion by monoclonal anti-CD20 antibody therapy or a reduction of activated T cells by LFA3-IgG fusion protein on moderate-to-severe AD. All patients treated with either rituximab or alefacept showed an improvement of their skin symptoms with a sust...
Source: Chemical Immunology and Allergy - December 2, 2014 Category: Allergy & Immunology Tags: Chem Immunol Allergy Source Type: research

Fatal Coxsackie meningoencephalitis in a patient with B-cell lymphopenia and hypogammaglobulinemia following rituximab therapy.
PMID: 26048250 [PubMed - as supplied by publisher]
Source: Annals of Allergy, Asthma and Immunology - June 2, 2015 Category: Allergy & Immunology Authors: Palacios T, Bartelt L, Scheld W, Lopes MB, Kelting SM, Holland S, Lipkin WI, Quan PL, Borish L, Lawrence M Tags: Ann Allergy Asthma Immunol Source Type: research

Production and Characterization of New Anti-Human CD20 Monoclonal Antibody.
Abstract The B-cell CD20 antigen is one of the most reliable surface targets in immunotherapy of B lymphoma. In this project, we studied the production and characterization of a new monoclonal antibody against chimeric human CD20 extra loops (hCD20 exl). The results showed that clone C12H, IgG2/k isotype reacted with the antigen in ELISA and immunoblot. The Kd value was  found to be 2×10-9M and flow cytometry results showed that 99.9% and 99.7% of the Daudi and Raji cells respectively were stained with C12H monoclonal antibody (mab) but not with Jurkat cell lines. It also effectively competed with Rituximab, thu...
Source: Iranian Journal of Allergy, Asthma and Immunology - October 1, 2015 Category: Allergy & Immunology Authors: Fasihi-Ramandi M, Amani J, Salmanian A, Moazzeni S, Ahmadi K Tags: Iran J Allergy Asthma Immunol Source Type: research

Asthma and orbital immunoglobulin G4-related disease.
CONCLUSION: Asthma is commonly associated with orbital IgG4-RD and generally manifests as adult-onset bronchial wall thickening seen at computed tomography, increased serum IgG4 levels, and good rituximab response. PMID: 26782673 [PubMed - as supplied by publisher]
Source: Annals of Allergy, Asthma and Immunology - January 9, 2016 Category: Allergy & Immunology Authors: Baqir M, Garrity JA, Vassallo R, Witzig TE, Ryu JH Tags: Ann Allergy Asthma Immunol Source Type: research

Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema.
PMID: 27017557 [PubMed - as supplied by publisher]
Source: Annals of Allergy, Asthma and Immunology - March 23, 2016 Category: Allergy & Immunology Authors: Motosue MS, Howard MT, Butterfield JH Tags: Ann Allergy Asthma Immunol Source Type: research

Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist.
CONCLUSION: Hypersensitivity reactions and immune dysregulation from biologic agents are not rare. The allergist and immunologist should be involved in managing these patients for optimal care. PMID: 27499538 [PubMed - in process]
Source: Annals of Allergy, Asthma and Immunology - July 31, 2016 Category: Allergy & Immunology Authors: Khan DA Tags: Ann Allergy Asthma Immunol Source Type: research

Modern challenges of allergic bronchopulmonary aspergillosis diagnosis and management: Finding from a case study with a history of rituximab use.
PMID: 28668248 [PubMed - in process]
Source: Annals of Allergy, Asthma and Immunology - July 1, 2017 Category: Allergy & Immunology Authors: García-Granero DB, Vera DG, Grande C, Jimenez RB, Rodriguez CF, Bobolea I Tags: Ann Allergy Asthma Immunol Source Type: research